Products - Oesophageal cancer | Topic | NICE

Showing 9 products

Date | Sort by Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
27 January 2016
Nivolumab for treating unresectable advanced oesophageal cancer when standard chemotherapy has failed [ID1249]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
6 January 2021
Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer ID1168
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma ID1305
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trifluridine–tipiracil for treating metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID1507]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC